Korro Bio (NASDAQ:KRRO) Receives New Coverage from Analysts at William Blair

William Blair began coverage on shares of Korro Bio (NASDAQ:KRRO) in a research note issued to investors on Wednesday, MarketBeat Ratings reports. The firm issued an outperform rating and a $180.00 price objective on the stock.

Other equities research analysts have also recently issued reports about the company. BMO Capital Markets reaffirmed an outperform rating and set a $120.00 price target on shares of Korro Bio in a report on Wednesday, May 15th. HC Wainwright reaffirmed a buy rating and set a $100.00 price target on shares of Korro Bio in a report on Tuesday, May 21st. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of Buy and an average target price of $135.00.

Korro Bio Price Performance

Shares of Korro Bio stock traded up $4.58 during midday trading on Wednesday, hitting $44.29. 19,603 shares of the company were exchanged, compared to its average volume of 50,006. Korro Bio has a 52 week low of $9.15 and a 52 week high of $97.91. The firm has a 50 day simple moving average of $41.15 and a 200-day simple moving average of $53.12.

Korro Bio (NASDAQ:KRRO) last posted its earnings results on Tuesday, August 13th. The company reported ($2.43) EPS for the quarter, missing the consensus estimate of ($2.39) by ($0.04). On average, sell-side analysts forecast that Korro Bio will post -9.64 EPS for the current fiscal year.

Institutional Investors Weigh In On Korro Bio

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Atlas Venture Life Science Advisors LLC increased its holdings in Korro Bio by 1.6% in the second quarter. Atlas Venture Life Science Advisors LLC now owns 1,137,149 shares of the company’s stock valued at $38,515,000 after purchasing an additional 17,857 shares during the last quarter. NEA Management Company LLC grew its stake in Korro Bio by 1.7% in the second quarter. NEA Management Company LLC now owns 1,090,793 shares of the company’s stock valued at $36,945,000 after acquiring an additional 17,857 shares during the period. Eventide Asset Management LLC acquired a new position in Korro Bio in the fourth quarter valued at about $26,185,000. 72 Investment Holdings LLC acquired a new position in Korro Bio in the fourth quarter valued at about $13,269,000. Finally, Monashee Investment Management LLC acquired a new position in Korro Bio in the fourth quarter valued at about $4,352,000. Institutional investors own 13.18% of the company’s stock.

Korro Bio Company Profile

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).